High out-of pocket costs limit access to lifesaving specialty drugs

Specialty drugs have become important treatment options for many serious and chronic diseases, and in some conditions like cancer they represent the only chance for long-term survival. But, insurers increasingly require patients to share the high costs of these medications. Two new studies have found evidence that such cost-sharing arrangements are associated with significant reductions in access to these drugs.